Denali Therapeutics (DNLI) Other Working Capital Changes (2017 - 2026)

Denali Therapeutics (DNLI) has reported Other Working Capital Changes for 10 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q4 2023, Other Working Capital Changes fell 101.21% year-over-year to -$379000.0; the TTM figure through Dec 2023 stood at -$379000.0 (changed N/A YoY), while the FY2023 annual figure was -$379000.0, changed N/A from the prior year.
• Other Working Capital Changes rose to $2.3 million in Q1 2026 per DNLI's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $31.3 million in Q4 2022 and bottomed at -$27.9 million in Q1 2022.
• Historically, Other Working Capital Changes has averaged $715588.2 across 5 years, with a median of -$87000.0 in 2023.
• On a YoY basis, Other Working Capital Changes climbed as much as 948.97% in 2024 and fell as far as 20257.47% in 2024.
• Denali Therapeutics' Other Working Capital Changes stood at $1.4 million in 2022, then jumped by 336.97% to $6.0 million in 2023, then tumbled by 102.42% to -$145000.0 in 2024, then sank by 1104.83% to -$1.7 million in 2025, then jumped by 231.14% to $2.3 million in 2026.
• Business Quant data shows DNLI's Other Working Capital Changes at -$379000.0 in Q4 2023, $31.3 million in Q4 2022, and -$3.4 million in Q3 2022.